Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Targeting genetic variants in mCRPC to improve survival outcomes

Susan Halabi • 2 Jun 2024
ASCO 2024
Genitourinary Cancer Prostate Cancer

Susan Halabi, PhD, FSCT, FASA, FASCO, Duke University Medical Center, Durham, NC, highlights the impact of genetic variants such as PTEN loss, RB1 loss, and AR gain on overall survival (OS) in metastatic castrate-resistant prostate cancer (mCRPC). Future clinical trials are anticipated to target these specific genetic alterations to improve patient prognosis and outcomes, similar to the use of PARP inhibitors in patients with breast cancer who have BRCA mutations. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Employment – ASCO
Consulting or Advisory Role – Aveo; Bristol-Myers Squibb; CG Oncology; J&J; Sanofi
Research Funding – Astellas Pharma (Inst)

More from Susan Halabi

Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
1:42
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
Susan Halabi • 29 May 2026
Clinical adoption of ctDNA assays into treatment decisions for mCRPC
0:46
Clinical adoption of ctDNA assays into treatment decisions for mCRPC
Susan Halabi • 29 May 2026
ctDNA prognostic model for rPFS in mCRPC: Alliance A031201 analysis
2:17
ctDNA prognostic model for rPFS in mCRPC: Alliance A031201 analysis
Susan Halabi • 30 May 2026
ctDNA models for predicting survival outcomes in mCRPC
1:32
ctDNA models for predicting survival outcomes in mCRPC
Susan Halabi • 2 Jun 2024

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals